Cross-source consensus on what matters today in genetics and genomics — drawn from 16 trusted public sources including NHGRI, the CDC, NHS England, Genomics England, the PHG Foundation, the Wellcome Sanger Institute, and peer-reviewed open-access journals.
Last updated: · browse archive
Stanford geneticist Euan Ashley argues that Claude completing a whole-genome analysis in under an hour for roughly $5 has outpaced the ethical and regulatory frameworks governing such outputs.
An FDA advisory committee has concluded that the benefits of Galleri, a circulating-tumour-DNA screening test covering multiple cancer types, outweigh its risks.
A 30-patient trial found that removing CD33 from donor haematopoietic stem cells allowed a CD33-directed cancer therapy to attack leukaemia whilst leaving the engrafted healthy cells intact.
A UK-first pilot across specialist centres in England aims to cut the time from biopsy to definitive brain tumour diagnosis from weeks to days using genomic profiling.
Researchers have shown that the APOE4 genetic risk variant for Alzheimer's disease actively disrupts cerebrovascular function and protein-clearance systems, and some of these effects could be reversed experimentally.
A yeast-complementation deep mutational scan of nearly all XPD amino acid substitutions separates ERCC2 variants that disrupt nucleotide excision repair from those that disrupt transcription, offering a functional framework for interpreting pathogenic variants in xeroderma pigmentosum and trichothiodystrophy.
A PLOS Genetics study systematically evaluates nearly 382,000 missense variants across 224 deafness genes, finding protein misfolding to be a common but under-recognised mechanism and offering a scalable approach to reclassifying variants of uncertain significance.
A preprint from Cold Spring Harbor Laboratory shows that loss of Tet2 and Tet3 in mouse immune cells consistently selects for trisomy 17, offering a mechanistic window into how epigenetic mutations may fuel blood cancers.
A large-scale single-cell genomics preprint spanning over 1.7 million cells from neurofibromatosis type 1 donors finds that somatic second-hit mutations in NF1 occur widely but are positively selected almost exclusively in oligodendrocytes and their precursors.
Four-year follow-up data for AMT-130 continue to show slowed disease progression compared with natural history, but the magnitude of benefit is smaller than reported at three years.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List